Arcellx, Inc.

Arcellx is a clinical-stage biotechnology company developing immunotherapies for hematologic malignancies and other difficult-to-treat diseases. The company's primary focus is on engineered cell therapies, particularly its dual-domain CAR (ddCAR) platform. Its most advanced program, anitocabtagene autoleucel, is in Phase 2 clinical trials for relapsed or refractory multiple myeloma and is being co-developed with Kite Pharma under a strategic alliance. The company also maintains an early-stage pipeline including ACLX-001 targeting BCMA, ACLX-002 targeting CD123 for acute myeloid leukemia and myelodysplastic syndrome, and preclinical candidates for solid tumor applications.

As a preclinical to Phase 2 biotechnology firm, Arcellx operates without significant commercial revenue, with development costs representing its primary cash outflow. The company is headquartered in Redwood City, California, with operations limited to the United States. Arcellx maintains a lean operational footprint with approximately 163 full-time employees. The company was incorporated in Delaware in 2014 and was formerly known as Encarta Therapeutics before adopting its current name in 2016. Its market capitalization of approximately $4.0 billion reflects investor expectations regarding its clinical programs and platform technology.